论文部分内容阅读
目的探讨诺和锐30联合阿卡波糖治疗2型糖尿病肥胖患者的临床疗效。方法选择我院2010年7月-2011年6月收治的82例2型糖尿病肥胖患者给予诺和锐30治疗,2次/d于餐前皮下注射,根据患者血糖水平对注射剂量进行调整,同时3次/d口服阿卡波糖150 mg,进餐时服用,连续治疗4周。比较治疗前后患者空腹血糖(FPG)、餐后2h血糖(2h PG)、糖化血红蛋白(GHbA1c)、胆固醇(Tch)、甘油三脂(TG)水平的变化,并观察患者药物不良反应的发生情况。结果 2型糖尿病肥胖患者经过4周治疗后,FPG为6.58±1.84mmol/L、2h PG为8.12±1.61mmol/L、GHbA1c为8.04±1.52%、Tch为1.69±0.14mmol/L、TG为4.58±1.05mmol/L,与治疗前相比明显降低,差异具有统计学意义(P<0.05)。3例患者发生低血糖反应,6例患者出现轻度消化道症状,主要为腹泻与腹胀,未出现任何严重不良反应。结论诺和锐30特充联合阿卡波糖治疗2型糖尿病肥胖患者具有安全、有效、不良反应少的优点,具有重要的临床应用价值。
Objective To investigate the clinical efficacy of Novo-Rui 30 combined with acarbose in the treatment of type 2 diabetic obese patients. Methods Eighty-two patients with type 2 diabetes mellitus and obesity admitted from July 2010 to June 2011 in our hospital were treated with Novo-Rui-Ru 30 and subcutaneously injected 2 times a day before meals. The injection dose was adjusted according to the blood glucose level of the patients. Meanwhile, 3 times / d oral acarbose 150 mg, taking meals, continuous treatment for 4 weeks. The changes of fasting blood glucose (FPG), 2h PG, GHbA1c, Tch and TG levels in patients before and after treatment were compared. The incidence of adverse drug reactions was also observed. Results The FPG was 6.58 ± 1.84mmol / L in FPG patients with type 2 diabetes mellitus after treatment for 4 weeks, 8.12 ± 1.61mmol / L for PG for 2h, 8.04 ± 1.52% for GHbA1c, 1.69 ± 0.14mmol / L for Tch and 4.58 ± 1.05mmol / L, which was significantly lower than that before treatment (P <0.05). Hypoglycemia occurred in 3 patients, mild gastrointestinal symptoms in 6 patients, mainly diarrhea and abdominal distension, and no serious adverse reactions occurred. Conclusions Nuo-Rui-Ru-Ru-30 combined with acarbose treatment of type 2 diabetic patients with obesity is safe, effective, with fewer adverse reactions, has important clinical value.